Abstract

The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infections collected from 0 to 209 days after onset of symptoms. Of 115 sera collected ≥61 days after onset of illness tested using plaque reduction neutralization (PRNT) assays, 99.1% remained seropositive for both 90% (PRNT90) and 50% (PRNT50) neutralization endpoints. We estimate that it takes at least 372, 416 and 133 days for PRNT50 titres to drop to the detection limit of a titre of 1:10 for severe, mild and asymptomatic patients, respectively. At day 90 after onset of symptoms (or initial RT-PCR detection in asymptomatic infections), it took 69, 87 and 31 days for PRNT50 antibody titres to decrease by half (T1/2) in severe, mild and asymptomatic infections, respectively. Patients with severe disease had higher peak PRNT90 and PRNT50 antibody titres than patients with mild or asymptomatic infections. Age did not appear to compromise antibody responses, even after accounting for severity. We conclude that SARS-CoV-2 infection elicits robust neutralizing antibody titres in most individuals.

Highlights

  • The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century

  • Of 234 sera collected from individuals 15–209 days after onset of illness, 98.7% and 99.6% were positive by PRNT90 and PRNT50 antibody tests, respectively (Supplementary Table 3)

  • The individual data-points for PRNT90 (Fig. 1) and PRNT50 (Fig. 2) for each serum are shown for the cohort as a whole, and stratified into those with severe disease, mild disease, or asymptomatic infections

Read more

Summary

Introduction

The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Many studies have reported antibody responses in COVID-19 patients using ELISA or other binding assays, but there are fewer reports using virus neutralization tests. Ill patients are reported to have higher peak neutralizing antibody titers[17,19,20].

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.